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Abstract
The cells that make up blood vessel walls appear to participate
actively in local immune and inflammatory responses, as well
as in certain vascular diseases. We tested here whether smooth
muscle cells (SMC) can produce the important inflammatory
mediator IL6. Unstimulated SMC in vitro elaborated 5 X 103
pg recIL6/24h (i.e., biological activity equivalent to 5 X 103 pg
recombinant IL6 (recIL6), as determined in B9-assay with a
recIL6 standard). Several pathophysiologically relevant fac-
tors augmented IL6 release from SMC including 10 ,tg LPS/
ml (104 pg recIL6), 10 ng tumor necrosis factor/ml (4 X 104 pg
recIL6), and most notably 10 ng ILl/ml (2 3.2 X 105 pg
recIL6). Production of IL6 activity corresponded to IL6
mRNA accumulation and de novo synthesis. SMC released
newly synthesized IL6 rapidly, as little metabolically labeled
material remained cell-associated. In supernatants of ILl-
stimulated SMC, 1L6 accounted for as much as 4% of the
secreted proteins.
In normal vessels SMC seldom divide, but SMC prolifera-
tion can occur in hypertension or during atherogenesis. We
therefore tested the relationship between IL6 production and
SMC proliferation in response to platelet-derived growth fac-
tor (PDGF) in vitro. Quiescent SMC released scant IL6 activ-
ity, whereas PDGF (1-100 ng/ml) produced concentration-de-
pendent and coordinate enhancement ofSMCproliferation and
IL6 release (linear regression ofgrowth vs. IL6 release yielded
r > 0.9). IL6 itself neither stimulated nor inhibited SMC
growth or IL6 production. Intact medial strips studied in
short-term organoid culture produced large quantities ofIL6,
similar to the results obtained with cultured SMC. These find-
ings illustrate a new function ofvascular SMC by which these
cells might participate in local immunoregulation and in the
pathogenesis of various important vascular diseases as well
as in inflammatory responses generally. (J. Clin. Invest.
1990.85:731-738.) ILl * SMC -cytokines - vasculitis *athero-
sclerosis
Introduction
Localized host defense reactions and pathways of immuno-
pathologic tissue damage often involve substantial alterations
in the functions of blood vessels. Recent evidence suggests
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heretofore unsuspected active participation ofboth major cell
types ofthe vascular wall, endothelium, and smooth muscle,
in many immune and inflammatory responses. For example,
these cells can both respond to and produce certain mediators
ofimmunity and inflammation, e.g., the cytokine ILl (1-4).
In addition to its well known systemic effects, ILl can partici-
pate in activation ofT lymphocytes, alter the hemostatic bal-
ance ofendothelial cells(EC)' (5, 6), promoteleukocyteadher-
ence to endothelia (7, 8), and augment the production ofvar-
ious mediators by vascular cells (e.g., prostanoids,
platelet-activating factor, and ILl itself) (9-12).
IL6, another pleiotropic cytokine originally described as a
variety ofbiological activities (13-15), is a major regulator of
the acute phase response (16) and stimulates lymphocyte pro-
liferation, aswell asdifferentiation ofandantibodyproduction
by B cells (17). Other possible actions ofIL6 include modula-
tion oftheproliferation ofnonlymphoid cells(18) oranti-viral
activity(14). IL6 isgenerally considered aproduct ofactivated
mononuclear phagocytes and fibroblasts, although vascular
endothelium and other cell types can also produce this cyto-
kine (19-21). Smooth muscle cells (SMC) by far outnumber
EC in the types ofblood vessels generally involved in regional
immune responses (venules) or major vascular diseases (mus-
cular arteries). Since SMC can generate certain immunosti-
mulatory cytokines such as ILl or tumor necrosis factor
(TNF)(22), wetestedwhetherthiscelltype mightalsoproduce
IL6, a more recently recognized T and B cell activator. We
found that SMC can not only express the IL6 gene in a regu-
lated manner, but that it constitutes a majorsecretory product
ofthese cells after ILl stimulation. Furthermore, proliferating
SMCs exhibit increased IL6 elaboration, which might contrib-
ute to activation ofT lymphocytes found in atheromata orthe
angiocentric lymphomatoses (23-27). SMC-rich short-term
organoid cultures ofmedial strips, not subjected to passage in
cell culture, confirmed the ability ofcultured human vascular
SMC to secrete large quantities ofIL6. Ourfindingsillustratea
novel pathway by which SMC might participate in local im-
munoregulation and in the pathogenesis ofvarious important
vascular diseases as well as in inflammatory responses gener-
ally.
Methods
Cellcultureandstimulation ofSMC. Human SMCs were isolated and
characterized asdescribed (I 1). The use ofthis usuallydiscarded tissue
was approved by the Human Investigation Review Committee ofthe
New England Medical Center. Explant-derived SMCs (28) were main-
tained in DME containing 10% FCS, antibiotics, L-glutamine, and
1.Abbreviations usedinthispaper:EC,endothelial cell; IT, insulinand
transferrin; PDS, plasma-derived serum; PDGF, platelet-derived
growth factor; recIL6, recombinant IL6; SMC, smooth muscle cell;
TNF, tumor necrosis factor.
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contained < 40 pg/ml of LPS as determined in our laboratory by
chromogenic Limulus amebocyte assay. The cellsexhibited thetypical
"hill and valley" growth morphology ofSMC and many reacted with
the monoclonal antibody HHF-35 which selectively recognizes muscle
formsofactin but doesnotreact with EC orfibroblasts(29). Cellswere
cultured at 20,000 SMC/cm2 and incubated 3 d. The medium was
replaced by fresh medium and stimuli were added for the indicated
time.
Preparation oftissue culturesfrom human saphenous veins. Excess
portions of human saphenous veins, harvested for coronary artery
bypasssurgery, weretransported inheparinizedbloodofthedonorand
processed immediately. The veins were washed four times in DME to
removeblood, and cut into portions of I cm in length. These pieces of
veins were then cut longitudinally and again washed in DME. The
connective tissue and the adventitia were stripped from the medial
layerwith two forceps. The remaining tissue, consisting ofintima and
media, was washed and cut into 2 X 2-mm portions. For each condi-
tion, four ofthese pieces were incubated together in insulin and trans-
ferrin-containing medium (IT-medium, described below) in 16-mm
wells. After48 h, thetissueswerecarefullywashed fourtimeswithfresh
medium,and IT-medium with orwithoutteststimuli wasadded for24
h. The supernatants were harvested and centrifuged at 1,500 g, FCS
(5%) was added, and samples were stored at -20'C until analyzed by
B9-assay. The tissue pieces were washed three times, IT-medium con-
taining 5% FCS was added, the tissue pieces were frozen for 2 h at
-200C, mechanically disrupted, celldebriswasremovedbycentrifuga-
tion, and the clarified extracts were used for determination ofcell-as-
sociated IL6.
AssayforIL6 activity. Cells ofthe hybridoma line B9, kindly pro-
vided by L. A. Aarden (30, 31), were cultured in DME containing
L-glutamine, antibiotics, 2-mercaptoethanol (5 X 10-5 M), recombi-
nant IL6 (recIL6), and 10% FCS (B9-medium). Serial fourfold dilu-
tionsofsampleswereprepared in 100Ml ofB9-medium lackingrecIL6.
Cellswerecentrifugedtwicein B9-medium withoutrecIL6,adjustedto
40,000cell/ml, and 100gIIofthiscellsuspension wasaddedto 100 l of
thediluted samples. Thecultureswere incubated for72 h, andexposed
for the last 4 h ofculture to [3H]TdR (6.7 Ci/mmol; 0.5 MCi perwell).
The cells were harvested onto glass fiber filters, using a cell harvester
(model PHD; Cambridge Technology, Inc., Cambridge, MA) and an-
alyzed in a liquid scintillation counter. Efficiency of counting was
determined with an external standard and results were expressed as
disintegrations per minute. The mean oftriplicate cultures was deter-
mined and biological activity was calculated by probit analysis ac-
cording to the method described for IL2 (32). The biological activity
was defined using serial fourfold dilutions ofsamples and recIL6 (10
ng/ml) which was used as standard in every B9-assay.
Assayfor mitogenic activity. SMC were cultured in 96-well flat-
bottom culture plates at a cell concentration of 1 X 105/cm2. After
overnightincubation, medium wasreplacedbyserum-free IT-medium
(33), compounded from DME and Ham's F12 (1:1, vol:vol), supple-
mented with insulin (I MM), and transferrin (5 gg/ml). Cells were
cultured for48 h, medium wasreplaced, andstimuli wereadded for24
h. Parallel cultures were either analyzed for IL6 activity orexposed to
[3H]TdR foradditional 24 h(6.7 Ci/mmol; 0.5 MCiperwell), cellswere
harvested, and thymidine incorporation was measured. Efficiency of
counting was determined by use ofan external standard.
Immunoprecipitation of metabolically labeled proteins. SMC
(20,000/cm2) were cultured in 150-mm dishes for 72 h, washed twice
in DME, and incubated with or without stimulus for 24 h in RPMI
1640 lacking unlabeled cysteine and methionine, containing L-gluta-
mine, antibiotics, 5% FCS, and 100 MCi/ml of Tran35S-labelP (ICN
Biomedicals Inc., Irvine, CA). The supernatants were removed and
equilibrated in immunoprecipitation buffer (50 mM Tris-HCl, 0.1%
SDS, 1% sodium deoxycholate, 1% NP-40, 150 mM NaCl, 5 mM
EDTA, 20 Mg/ml soybean trypsin inhibitor, 0.1 mM PMSF, 5 JAM
antipain, and 5 MuM leupeptin, pH 7.4) by centrifugation in a Centri-
con-3 device (Amicon Corp., Danvers, MA) at 4VC. The samples (1
ml) were "precleared" by addition ofnonimmune rabbitserum(10Ml),
and absorption with fixed staphylococci (IgG-Sorb; The Enzyme
Center, Malden, MA). After incubation for 2 h, immune complexes
were precipitated by centrifugation (20 min, 1,500 g, 4VC). IL6 anti-
body (10 Ml) was added for 24 h and precipitated with fixed staphylo-
cocci. The pelletswere washed threetimeswith washingbuffer(50mM
Tris-HCl, 0.02% SDS, 0.1% NP-40, 0.5 M NaCl, 5 mM EDTA, 0.1
mM PMSF, 20Mg/ml soybean trypsin inhibitor, 5MM leupeptin, and 5
MM antipain, pH 7.4), and once with 62.5 mM Tris-HCl. The pellets
were then resuspended in SDS-PAGE sample buffer (62.5 mM Tris-
HC1, 2.3% SDS, 5% 2-mercaptoethanol, 10% glycerol, and 1 mg/ml
bromphenol blue, pH 7.4) and heated at 950C for 10 min. Samples
were centrifuged and the supernatant was electrophoresed on a 12.5%
SDS-PAGE gel (30 min, 20 mA; 2 h, 40 mA). Gels were fixed in 10%
glacial acid and 30% methanol (1 h), washed inwater(30min),treated
with Fluorohance (30 min; Research Products International Corp.,
Mount Prospect, IL), dried for 2 h, and fluorographed at -70°C for
7 d.
We quantified the amount of specifically precipitated proteins in
supernatants ofunstimulated LPS or ILI-stimulated cells. The super-
natants were equilibrated and concentrated in immunoprecipitation
buffer. Twosamples(10Ml) ofeach ofthesesupernatantswere addedto
100 Ml immunoprecipitation buffer, respectively. Sample one was pre-
cipitated in 10% TCA, to quantify the total amount ofde novo-pro-
duced protein. Sample two wasprecipitated with recIL6 antiserum (10
,ul) asdescribed above, and run on a 12.5% SDS-PAGEgel. Thegel was
cut in 0.5 cm slices, each was solubilized in 30% H202, and counted in
a liquid scintillation counter. The radioactivity (disintegrations per
minute) contained in the specific bands was used for calculation of
specifically precipitated proteins.
Isolation ofRNA and hybridization ofNorthern blots. SMC incu-
bated with or without the stimuli were lysed in guanidine-isothiocya-
nate (4 M) (34), and RNA was extracted and precipitated twice after
theprotocol ofChomczynskiandSacchi (35). RNAofSMC(10Mg/ml)
wasapplied to a 1.2% agarosegelcontaining formaldehyde (36), run at
35 V overnight, blottedtoanylon membranebycapillary transfer, and
fixed by ultraviolet (UV) illumination for 2.5 min on each side. The
membrane was prehybridized for 2 h and hybridized overnight with
32P-labeled IL6 cDNA (13, 14, and 37). Autoradiography was per-
formed using X-Omat AR film (Eastman Kodak Co., Roches-
ter, NY).
Results
Production ofIL6 activity bySMC. Human SMC cultured for
24 hwithout addition released some IL6 activity (Fig. 1 A), but
incubation with LPS, TNF, or platelet-derived growth factor
(PDGF) enhanced IL6 production. ILl greatlyaugmented IL6
production by SMC over a range ofconcentrations (Fig. 1 B).
In order to determine possible functions of IL6, we analyzed
whetherit inducesits own production in SMC. Cellsincubated
with exogenous recIL6 for 6 h, then washed and incubated for
additional 18 h in fresh medium without recIL6 released no
IL6 activity, although SMClikewise exposed to ILl did secrete
IL6 (data not shown). Addition of antibody raised against
recIL6 (diluted 1:200) inhibited IL6 activity of LPS or ILl-
stimulated SMC supernatants in B9-assay by 99% (data not
shown). Even maximally effective concentrations of LPS
caused a 100-fold-less IL6 release from SMCthan thatelicited
by ILl.
Time course ofIL6 production. We analyzed the effect of
various mediators on the kinetics ofIL6 secretion over 144 h
(Fig. 2). Release ofIL6 activity from SMC began after 3 h of
incubation with ILI (filled arrow) and increased continuously
thereafter. LPS was a relatively weak inducer ofIL6 through-











Figure 1. (A) IL6 activity in supernatants ofhuman SMC. Cells
(20,000/cm2) were cultured 72 h, medium was replaced, and stimuli
were added for 24 h. The concentration ofLPS was 10Ag/ml and of
all other stimuli 10 ng/ml. (B) SMC were stimulated with various
concentrations ofILla. IL6 activity in supernatants was measured
using the B9-assay.
out the entire time course, yielding maximal twofold increases
compared with unstimulated SMC.
Influence ofproliferation on IL6 production. Since SMC
proliferation increases in certain pathological states, we inves-
tigated the relationship between growth state and IL6 elabora-
tion by these cells. Recombinant PDGF (c-sis homodimer)
produced concentration-dependent stimulation of [3H]TdR
incorporation, a valid index of human SMC multiplication
under these conditions (38). IL6 production by these cells in-
creased linearly as a function of proliferative rate (linear re-
gression of growth vs. IL6 release yielded r > 0.9) (Fig. 3).
Experiments performed in a defined medium (IT-medium,
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Figure 2. Time course ofIL6 release. Unstimulated SMC or cells
stimulated with LPS or ILl were cultured in parallel for up to 144 h.
IL6 activity in supernatants was determined as above. The arrows
mark the IL6 activity ofILl-stimulated (filled) or unstimulated SMC







Figure 3. SMCs were cultured in FCS-containing medium at
100,000/cm2 for 24 h, medium was replaced by three washes ofIT-
medium, and cultured for 48 h. Parallel cultures were then incubated
with or without PDGF (c-sis; 0, I ng/ml, 10 ng/ml, or 100 ng/ml) in
the designated medium (IT- or PDS-medium; PDS-medium is com-
pounded ofIT-medium and 10% PDS) for further 24 h and either
analyzed for IL6 in the B9-assay or thymidine incorporation (from
24-48 h after stimulation), as a measure for cell proliferation. The
graph depicts the relationship between cell proliferation and IL6 re-
lease in the various conditions (from left to right: 0, 1, 10, or 100
ng/ml PDGF) in either IT- or PDS-containing medium.
medium containing plasma-derived serum (PDS, Fig. 3, right),
which is low in mitogens but contains many undefined nutri-
tive factors lacking in the serum-free IT-medium. Under con-
ditions in which ILl and PDGF produced approximately
equivalent increases of cell number, IL6 release of recILl-
treated SMC by far exceeded that of PDGF incubated cells
(data not shown). Thus, ILl's inductive effect on IL6 produc-
tion is not solely related to its proliferative action.
SMCs produce IL6 de novo. Metabolic labeling and im-
munoprecipitation experiments determined whether SMC re-
leased preformed or newly synthesized proteins. Unstimulated
SMC released labeled proteins of the expected sizes (Fig. 4),
consistent with the presence of biological IL6 activity, mea-
sured independently. ILl prompted much greater elaboration
oflabeled IL6 proteins than did LPS, a finding also in agree-
ment with our bioassay results. To elucidate the heterogeneity
ofspecifically immunoprecipitated IL6 bands on SDS-PAGE,
we performed experiments with tunicamycin, an inhibitor of
N-glycosylation. This treatment virtually eliminated two more
slowly migrating bands (arrowheads), an indication that these
proteins are N-glycosylated. The major precipitated protein
might be unglycosylated or O-glycosylated, since it was not
affected by this treatment. Cell lysates ofSMC contained little
IL6 protein, even after ILl treatment.
Quantification ofde novo IL6 synthesisandsecretion. ILl-
stimulated SMC released high amounts of IL6 activity sug-
gesting that IL6 is a major secretory product under these con-
ditions. We explored this question by calculating the portion
ofIL6 in total biosynthetically labeled proteins released from
ILI-stimulated SMC. IL6 accounted for about 4% of the se-
creted proteins (Table I). In contrast, ILI-stimulated EC pro-
duced only < 0.2% IL6 (data not shown).
Northern analysis ofmRNA derivedfrom SMC. To inves-
tigate whether IL6 production is regulated at the level of
translation or mRNA, we performed Northern analysis. Un-



















Figure 4. Radioimmunoprecipitation ofbiosynthetically labeled pro-
teins derived from SMC supernatants or cell lysates (2 Ag/ml tunica-
mycin [TM] was added to some cultures). Unstimulated, LPS- (10
gg/ml) orILl- (10 ng/ml) stimulated SMC were incubated 24 h in
presence of[35S]methionine-containing medium, lacking nonlabeled
methionine. Supernatants (SN) or cell-lysates (IC) were equilibrated
with precipitation buffer, precleared with normal rabbit serum, and
precipitated with rabbit antihuman recIL6 serum (for details see
Methods), run on a 12.5% SDS-PAGE gel, and visualized by autora-
diography. The arrowheads indicate proteins that disappear after
tunicamycin-treatment.
stimulated SMC lacked detectable IL6 mRNA (Fig. 5), as did
LPS-, TNF-, orIL6-stimulated cells. SMC incubated with ILl,
however, contained high levels of IL6 mRNA. Since SMC
released IL6 activity basally or after incubation with LPS, fail-
ure to detect IL6 mRNA under these conditions probably re-
flects insufficient sensitivity of the Northern analysis. In su-
Table L Quantification ofDeNovo-producedIL6
Radioactivity (35S; dpm) detected
in samples ofSMC treated
with different stimuli
Condition* Unstimulated LPS ILI
TCA-precipitated proteins
(100%) 692,900 1,100,935 878,708
IL6 protein fraction of 3,277 4,468 33,248
SDS-PAGE gel (0.47%)t (0.41%) (3.79%)
* 10 ul ofradiolabeled supernatant either completely precipitated by
TCA (100%) or immunoprecipitated, and run on a 12.5% SDS-
PAGE gel. Lanes were sliced horizontally, and radioactivity ofspe-
cific IL6 precipitates was detected.








Figure 5. Accumulation ofIL6 mRNA in SMC incubated with var-
ious stimuli for 24 h. Except LPS (10,g/ml), all stimuli were applied
at 10 ng/ml. Total RNA was isolated, 10 ag/lane were separated by
agarose gel electrophoresis, blotted to nylon membranes, and hybrid-
ized with IL6 probe (IL6) or directly visualized by UV illumination
(RNA).
perinduction experiments with the protein synthesis inhibitor
cycloheximide, unstimulated or LPS-stimulated SMC did
contain IL6 mRNA (Fig. 6). Cycloheximide also markedly
accentuatedthe IL6 signal inextractsofSMCtreatedwithIL1.
Saphenous vein segments produce IL6 during short-term
culture. The SMC shown above toproduce IL6 wereincubated
two to six passages in vitro before study and might be in a
"phenotypically modulated" state that differs from contractile
SMC in vivo. To ascertain whether SMC in situ might also
produce IL6 and to determine if they could produce high
amounts as do cultured SMC, we approached the in vivo con-
ditions as closely as possible by study ofshort-term organoid
cultures ofhuman saphenous veins. These tissues released sig-
nificant IL6 activity even without stimulus (Table II). Addi-
tion ofILl, TNF, or LPS increased the IL6 release. The tissue
extracts contained far less IL6 activity than the corresponding
supernatants. The anti-recIL6 antiserum inhibited the IL6 ac-
tivity in both supernatants and extracts by 2 92%. In other
experiments (data not shown) abrasion of the intima to re-
move completely the endothelium did not influence the pat-
tern ofIL6 production.
Discussion
Blood vesselsfigure prominently in a numberofclassic immu-
nopathologic processes. Well-recognized examples include





















Figure 6. Superinduction of 1L6 mRNA in SMC. Unstimulated,
LPS- (10 gg/ml) or ILl - (10 ng/mI) stimulated SMCs were incubated
in presence or absence ofcycloheximide (1 I g/ml) for 24 h, and total
mRNA was isolated and treated as described in Fig. 5.
Table H. Saphenous Vein Strips Produce 1L6
in Short-term Organoid Cultures
1L6 activity* in supernatants or lysates ofhuman
saphenous vein tissue pieces incubated with or
without rabbit antihuman recIL6 antiserum (AbWt
Supemeatants Cell-associated
Stimulus, -Abt +Ab -Ab +Ab
Unstimulated1l 530,400 25,200 11,700 1,275
264,900 16,500 3,150 298
ILl 3,693,300 132,600 46,800 2,930
4,547,100 132,600 40,800 2,072
TNF 1,847,100 71,100 40,800 1,465
1,399,500 71,100 16,500 1,367
LPS 1,305,900 267,300 21,900 1,803
1,060,800 43,800 28,800 2,734
*IL6 activity was measured in the B9-assay. TheIL6 activity was de-
termined with respect to recIL6 standard (10 ng/ml).
Rabbit antihuman recIL6 antiserum was applied at 1/1,000 dilu-
tion (Ab).
The stimuli were applied at the following concentrations: ILla, 10
ng/ml; TNF,10 ng/ml; and LPS ofSalmonella abortus equi,1 sg/ml.
11 The presented data are results derived by probit analysis of two in-
dependent cultures studied at each condition. Each culture contained
four tissue pieces.
immune complex diseases, the Arthus and Shwartzman reac-
tions, reaginic responses with increased vascular permeability,
and delayed-type hypersensitivity characterized by diapedesis
ofleukocytes from venules (39-42). The protein mediators of
immune and inflammatory responses, now known as cyto-
kines, appear to produce many oftheir local actions by altering
functions of vascular EC. Vessel wall cells not only serve as
targets of cytokines, but also produce these mediators. For
example, vascular EC and SMC can inducibly express genes
for both isoforms of ILl (3, 4). Under some circumstances,
human SMC can express the TNFa gene (22). Vascular EC
can also produce IL6 (19-21), a pleiotropic cytokine that
unites a number ofbiological functions previously known by
different names including B cell stimulatory factor-2 (43), he-
patic stimulatory factor (44), interferon #2 (45, 46), 26-kD
protein (47) or T cell activating factor (48).
We report here that vascular SMC, the most numerous cell
type in macrovessels, also express the IL6 gene and secrete very
high amounts ofthis mediator (ng/cell per 24 h) in response to
ILl, and to other pathophysiologically relevant stimuli to a
lesserdegree. The IL6 production in response to LPS might be
mediated by ILl, however, preliminary experiments failed to
provide evidence that autocrine ILl is responsible for 1L6 pro-
duction induced by LPS. The levels ofIL6 secreted by SMG by
far exceed those produced by EC cultured under similar cir-
cumstances. For SMC, as in other cell types (49), ILl appears
to be the most effective stimulus for 1L6 gene expression.
Quantitative metabolic labeling and immunoprecipitation ex-
periments established that 1L6 comprised
- 4% of the pro-
teins secreted by ILI-stimulated SMG. By contrast, in human
EC isolated from the same type of vessel, 1L6 accounted for
<0.2% ofthe total secreted protein even after ILl treatment.
Ourdata also indicate that SMM can modify newly synthesized
IL6 byN-glycosylation and secrete the cytokine without intra-
cellular accumulation.
Upon prolonged culture, SMCs undergo a characteristic
"phenotypic modulation" (50, 51) to a state that may resemble
that ofSMC in atheromata more closely than that of contrac-
tile SMC in the normal vessel. It waspossible that the capacity
to express IL6 genes depended on a phenotypic shift, as in the
case ofdecay accelerating factor (52), which is expressed in
atheromata and inpassaged SMC in culture, but not in normal
vascular tissue. We therefore examined production of IL6 ac-
tivity in short-term organoid cultures of saphenous veins.
SMC are by far the predominant cell type in these intima-
media strips. The tissues exhibited a pattern of basal and in-
duced IL6 production very similar to that observed in the
passaged cells in culture. These results support the concept
that SMC in vivo might be important producers ofIL6, since
these tissues, not subjected to culture and passage, secreted
large amounts ofthis mediator.
In contrast to ILl,IL6 lacks direct effects on EC andSMC
functions tested. Within the walls of diseased blood vessels,
locally producedIL6 might thus act to modulate the activities
of lymphocytes rather than those of intrinsic vascular cells.
ILI-inducedIL6 gene expression bySMC could amplifyILl's
stimulatory effects on T cell proliferation and account indi-
rectly for B cell stimulation previously attributed to ILl. Lym-
phocytic infiltration characterizes a number of types of vascu-
litis. While phenotyping studies have been limited, leukocytic
infiltrates in the walls ofvasculitic vessels include both B and T
cells (27, 53-56). Perivascular accumulation of T cells charac-




.:terize "angiocentric immunoproliferative" lesions such as
those found in lymphomatoid granulomatosis. The reason for
this congregation ofhyperplastic T cells around vessels is un-
known. We propose that the copious amounts ofthe lympho-
cyte activator IL6 secreted by SMC might help to explain this
pattern.
We further propose that SMC-derived IL6 may contribute
to T cell activation within regions ofthe evolving human ath-
erosclerotic lesion. Although the necrotic cores ofhuman ath-
eromatacontain lipid-laden macrophages (potential sourcesof
the T cell comitogens ILl and IL6), the active "shoulder"
region of human atherosclerotic plaques contains large num-
bers ofT lymphocytes and SMC but few ifany mononuclear
phagocytes (25, 26, 57). The T cells in this "shoulder" area
appear activated, as they express IL2 receptors (56). Many of
the SMC in the vicinity ofthe T cells within atheromata bear
MHC class II antigens. Immune interferon, a product ofacti-
vated T cells, is the only known inducer of class II HLA ex-
pression on human SMC(58). These findings all pointto local-
ization ofactivated T lymphocytesadjacent to SMC in areasof
evolving human atheromata that lack abundant macrophages.
In this situation, IL6 and/or ILl secreted by SMC may well
contribute to T cell activation.
In normal vessels, SMC divide little ifat all. During ath-
erogenesis, these cells, however, proliferate, probably due in
part to abnormal mitogenic stimulation (59). We report here
that cultured SMC dividing in response to PDGF augment
their IL6 release. During formation of human atheromata,
proliferating SMC may also release IL6, thereby furnishing
one stimulus for T cell activation. Increased production of
inflammation-related proteins bygrowing SMC may represent
a generalized response ofthese cells to mitogens as rat SMC
secrete apolipoprotein E(60)and rodent mesangial cellselabo-
rate ILI in a proliferation-dependent manner (61). Also, mi-
togenic stimuli augment IL6 (interferon #2) production in
mouse 3T3 cells (62) and FS-4 human fibroblasts (18).
In this regard, it is noteworthy that IL6 exhibited no mito-
genic or growth-inhibitory effect on cultured SMC. Exposure
to ILI does, however, promote SMC proliferation. Some orall
ofthis action may be due to stimulation ofautocrine PDGF-
AA gene expression by these cells (63). Nonetheless, our ex-
periments demonstrated that not all of ILl's stimulation of
IL6 production by these cells is due to increased cell division.
Our finding that vascular SMC in in vitro or organoid
cultures secrete large amounts ofIL6 afteractivation increases
our understanding ofthe possible mechanisms ofT cell acti-
vation within the blood-vessel wall during atherogenesis or
other pathological situations. Stimulation by locally produced
IL6 of B cell proliferation, differentiation, and antibody pro-
duction may also contribute to the pathogenesis of autoim-
mune and other forms ofvasculitis. In addition to these possi-
ble roles in pathogenesis ofvasculardiseases, IL6 derived from
activated SMC may also participate in regional immune re-
sponsesto invasive blood-borne infectious agentswithin vessel
walls. Our results increase knowledge ofthe repertoire ofim-
mune and inflammatory functions of intrinsic cells of the
blood-vessel wall and illustrate further the potential complex-
ity ofcytokine cascades at play in local host defense mecha-
nisms and in pathology.
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